Since the publication of the Osteoporosis Canada guide-lines in 2002, there has been a
paradigm shift in the prevention and treatment of osteoporosis and fractures. 1, 2 The focus …

Teriparatide (TPTD) is the only currently available therapeutic agent that increases the
formation of new bone tissue and can provide some remediation of the architectural defects …

Osteoporosis is a prevalent disease that affects more than 10million Americans. The lifetime
risk of an osteoporosisrelated fracture is 50% for Caucasian women and 25% for men. Hip …

Osteoporosis is characterized by the occurrence of fragility fractures. Over the past years,
various treatment options have become available, mostly antiresorptive agents such as …

Glucocorticoid-induced osteoporosis (GIOP) is one of the most important side effects of
glucocorticoid use, as it leads to an increased risk of fractures. Recently, many published …

The high worldwide prevalence of osteoporosis means it is considered a serious public
health concern, possibly leading to physical disability and an increased mortality rate …

Introduction Teriparatide significantly reduces fracture rates in clinical trials; however, those
study populations were relatively restricted and included too few patients to analyze fracture …

The effect of teriparatide and risedronate on back pain was tested, and there was no
difference in the proportion of patients experiencing a reduction in back pain between …

Despite evidence for higher fracture risk, clinical effects of osteoporosis treatments in type 2
diabetes (T2D) are largely unknown. Post hoc analyses of the DANCE observational study …

Teriparatide is a skeletal anabolic treatment for patients with osteoporosis at high risk for
fracture. Because adequate clinical trials have not yet been conducted to assess the efficacy …